重组人血管内皮抑素联合顺铂治疗恶性腹腔积液的临床观察
Clinical research on rhendostatin combined with cis-platinum on patients with maliganant peritoneal effusion
肖锋 1肖茂良 1唐友斌 1颜学军1
作者信息
- 1. 湖南中医药高等专科学校附属第一医院肿瘤一科 412000
- 折叠
摘要
目的：评价重组人血管内皮抑素（恩度）联合顺铂腹腔注射治疗恶性腹腔积液的疗效与安全性。方法：76例经病理确诊的晚期恶性肿瘤合并腹腔积液患者，行腹腔穿刺引流后，随机分为两组。试验组：腹腔注射重组人血管内皮抑素60毫克，顺铂40毫克 D1,4,7，三次为1周期；对照组：单用顺铂40毫克腹腔注射 D1,4,7，其余同试验组。按照WHO胸腹水疗效评价标准和NCI-CTC AE 4.0标准分别评估疗效及毒副反应。结果：试验组和对照组的客观有效率分别是65.7%和41.4%,，差异有统计学意义( p<0.05)；疾病控制率分别是94.2%和58.5%，差异有统计学意义( p<0.05)。试验组与对照组相比生活质量有改善的趋势。不良反应主要是白细胞减少，血小板下降，心脏毒性，恶心呕吐，两组无统计学差异( p>0.05)。结论：重组人血管内皮抑素（恩度）联合顺铂腹腔注射治疗恶性腹腔积液疗效好，毒副反应小，值得临床推广。
Abstract
OBJECTIVE:To observe the clinical efficacy of recombinant human endostain combined with cis-platinum in the treatment of patients with maliganant peritoneal effusion.METHODS:76 patinets with maliganant peritoneal effusion,who were diagnosed by pathology,were randomly divided into two groups after abdominocentesis.Trial group were treated with endostain 60mg and cis-platinum 40mg each time on d1,d4,d7;control group were treated with monotherapy of cis-platinum 40mg with the same procedure..The efficacy was evaluated according to WHO criteria and safety according to NCI CTC AE 4.0 version criteria..RESULTS The objective response rate was 65.7% for trial group and 41.4% for control group,the difference was stastical significance(p<0.05).The disease control rate was 94.2% for trial group and 58.5% for control group, the difference was stastical significance(p<0.05). Trial group showed a tendency to improve the quality of life compared to control group..Toxicities mainly included neutropenia、 thrombocytopenia 、Cardiac toxicity and nausea/vomiting,but the difference was not significant (p>0.05). CONCLUSION :Recombinant hunan endostatin combined with cis-platinum is an effective and safety therapy for malignant peritoneal effusion,with fewer toxic reaction,which is wothy of spreading in the clinic.
关键词
重组人血管内皮抑素/顺铂/恶性腹腔积液Key words
rh-endostatin/cis-platinum maliganant/peritoneal effusion引用本文复制引用
出版年
2014
NETL
NSTL
万方数据